[{"id":"fe7a5d8e-4b89-442a-960a-83aeeffb3ee8","acronym":"","url":"https://clinicaltrials.gov/study/NCT04790409","created_at":"2021-03-10T13:54:17.167Z","updated_at":"2024-07-02T16:35:37.014Z","phase":"Phase 2","brief_title":"Sintilimab Combined With Anlotinib in Advanced NSCLC With EGFR Uncommon Mutations","source_id_and_acronym":"NCT04790409","lead_sponsor":"Zhejiang Cancer Hospital","biomarkers":" PD-L1","pipe":" | ","alterations":" EGFR mutation • EGFR T790M • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR G719X + EGFR L861Q + EGFR S768I","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR T790M • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR G719X + EGFR L861Q + EGFR S768I"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Focus V (anlotinib) • Tyvyt (sintilimab)"],"overall_status":"Completed","enrollment":" Enrollment 21","initiation":"Initiation: 08/01/2019","start_date":" 08/01/2019","primary_txt":" Primary completion: 09/13/2023","primary_completion_date":" 09/13/2023","study_txt":" Completion: 09/13/2023","study_completion_date":" 09/13/2023","last_update_posted":"2023-09-14"}]